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A Single Quantiﬁable Viral Load Is Predictive of
Virological Failure in Human Immunodeﬁciency Virus
(HIV)-Infected Patients on Combination Antiretroviral
Therapy: The Austrian HIV Cohort Study
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Background. Viral loads (VLs) detectable at low levels are not uncommon in patients on combination antiretroviral therapy
(cART). We investigated whether a single quantiﬁable VL predicted virological failure (VF).
Methods. We analyzed patients receiving standard regimens with at least 1 VL measurement below the limit of quantiﬁcation
(BLQ) in their treatment history. The ﬁrst VL measurement after 6 months of unmodiﬁed cART served as baseline VL for the subse-
quent analyses of the time to reach single VL levels of ≥200, ≥400, and ≥1000 copies/mL. Roche TaqMan 2.0 was used to quantify
human immunodeﬁciency virus-1 ribonucleic acid. Factors associated with VF were determined by Cox proportional hazards models.
Results. Of 1614 patients included in the study, 68, 44, and 34 experienced VF ≥200, ≥400, and ≥1000 copies/mL, respectively. In
multivariable analyses, compared with patients who were BLQ, a detectable VL≤ 50 and VL 51–199 copies/mL predicted VF ≥ 200
copies/mL (hazards ratio [HR] = 2.19, 95% conﬁdence interval [CI] = 1.06–4.55 and HR = 4.21, 95% CI = 2.15–8.22, respectively). In
those with VL 51–199 copies/mL, a trend for an increased risk of VF ≥400 and VF ≥1000 copies/mL could be found (HR = 2.13, 95%
CI = 0.84–5.39 and HR = 2.52, 95% CI = 0.96–6.60, respectively).
Conclusions. These ﬁndings support closer monitoring and adherence counseling for patients with a single measurement of quan-
tiﬁable VL <200 copies/mL.
Keywords. cART; HIV; low-level viremia; viral load; virological failure.
The goal of combination antiretroviral therapy (cART) is to ob-
tain and maintain viral suppression. Although guidelines have
recommended viral loads (VLs) to be below the limit of quanti-
ﬁcation (BLQ) of clinically accessible assays [1–4], it remains un-
clear whether VLs detectable at low levels, typically below 200
copies/mL, are clinically important with regard to subsequent
treatment failures. At the time VL reveals 51 copies/mL or
more, it is uncertain how it will subsequently develop. It may pos-
sibly turn out to be only a viral blip, generally indicating episodes
of transiently detectable VL above 50 copies/mL [3, 5] followed
by a subsequent undetectable VL measurement, or persistent de-
tectable VL [4] or even virological failure (VF). Deﬁnitions of VF
vary between guidelines and, accordingly, some guidelines seem
to be more conservative, recommending lower levels of VL (>50
copies/mL) to be reviewed due to a potential risk of rebound [1].
Others deﬁned VF as having a VL of >200 copies/mL [2–4], and
one guideline sets higher thresholds for deﬁning VF, namely VL
of >1000 copies/mL [5]. Despite several investigations that fo-
cused on consequences of persistent low-level viremia (LLV),
which was determined by 2 or more VL measurements [6–12],
studies considering 1 single VL measurement to be predictive
of VF are very rare. Only 1 study observed patients with a single
quantiﬁable VL below 50 copies/mL to be at higher risk of re-
bound of >50 and >400 copies/mL [13]. Different commercial
techniques are able to detect VLs at low levels. It seems that
low-level, positive VL results appear to be more common with
some VL assays including the Roche Cobas AmpliPrep/Cobas
TaqMan 2.0 [14–16].However, this result needs to be conﬁrmed.
In this study, we present data from a cohort of well deﬁned
human immunodeﬁciency virus (HIV)-infected patients on un-
modiﬁed cART with standard regimens over a recent period of
more than 6 months in Austria. The aim of the study was to
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evaluate the impact of LLV, measured by TaqMan 2.0 assay, and
other factors that could increase risk of VF. Virological failure
was deﬁned as HIV ribonucleic acid (RNA) levels of ≥200,
≥400, and ≥1000 copies/mL.
PATIENTS AND METHODS
The Austrian HIV Cohort Study
The Austrian HIV Cohort Study (AHIVCOS) is an open, multi-
center, prospective, observational cohort study of HIV-infected
individuals observed at 7 HIV treatment centers in Austria.
The study was initiated in 2001 as an incorporated association
by representatives of 5 Austrian HIV treatments centers (AKH
Vienna, Otto-Wagner-Hospital Vienna, AKH Linz, LKH Inns-
bruck, and LKHGrazWest). In 2008, 2 additional HIV treatment
centers (LKH Salzburg and LKH Klagenfurt) joined AHIVCOS,
thus patients are currently enrolled actively and prospectively at
7 public hospital-based HIV treatment centers, which covers
approximately 80% of all treated HIV-infected patients in
Austria.
By July 1, 2014, AHIVCOS had included information on
8097 individuals. Demographic, clinical, laboratory, and treat-
ment data have been collected prospectively starting at the
time of inclusion into the cohort. Type of and changes in
cART, including reasons for interruptions, are recorded, as
well as the entire medication history including all drugs, dura-
tion of intake, and doses patients receive. Acquired immune de-
ﬁciency syndrome events as well as coinfections, such as
hepatitis B and C, syphilis, etc, were collected. Laboratory pa-
rameters were recorded continuously and measured in each sin-
gle center.
Study Design
A retrospective analysis was conducted of individuals on cART
who enrolled in AHIVCOS between July 1, 2012 and July 1,
2013. Approval for this study was obtained from the local eth-
ical committees of the following participating centers: Vienna
Medical University (No. 898/2010), City of Vienna (No. 12-
216-VK/2013), Salzburg Federal Government (No. 1159/
2010), Graz Medical University (No. 21-431/2010), Innsbruck
Medical University (No. 283/4.4/2009), Upper Austria Federal
Government (No. C-3-10/2010), and Carinthian Federal State
(No. A-13-11/2011). The patients gave written informed con-
sent to store their information in the hospital database and to
use the data for research.
Inclusion Criteria
Patients with at least 1 VL measurement BLQ after initiating
cART had to receive unmodiﬁed cART for more than 6 months
between July 1, 2012 and July 1, 2013 (N = 3299), irrespective of
therapies the patients might have taken before this period. Pa-
tients who were not on stable cART due to either interruptions
or switches were excluded. During these 6 months, patients
had to receive cART with 2 nucleoside reverse-transcriptase
inhibitors (NRTIs) and either a non-NRTI (NNRTI) or a boost-
ed protease inhibitor (PI/r) or an integrase inhibitor (INSTI).
Individuals with other cART regimens than those mentioned
above were excluded (N = 411). A total of 1010 patients did
not have any VL measurement between 6 and 12 months
after initiation of the respective cART regimen and were also ex-
cluded. We further excluded 103 individuals who never had VL
BLQ. In the end, 1775 patients fulﬁlled the inclusion criteria,
and their ﬁrst VL measurement between 6 and 12 months
after initiation of the respective cART regimen served as base-
line for the analyses of the time to single HIV RNA levels of
≥200, ≥400, and ≥1000 copies/mL, respectively (Figure 1).
In order to have a consistent lower limit of quantiﬁcation of
20 copies/mL, 5 of 7 HIV treatment centers that measured VL
by the Roche Cobas AmpliPrep/Cobas TaqMan 2.0 (Taqman,
Roche Diagnostics, Mannheim, Germany) were included in
the analysis. The remaining 2 centers used the Abbott RealTime
HIV-1 assay (Abbott Diagnostics, Wiesbaden, Germany) and
were excluded. The observation period ended in March 2014.
Deﬁnition of Low-Level Viremia and Virological Failure
All single quantiﬁable measurements of <200 copies/mL were
classiﬁed as LLV. For further analyses, LLV was divided into 2
categories: HIV RNA levels of 51–199 copies/mL and HIV
RNA levels of ≤50 copies/mL. Three deﬁnitions for VF were
used: the “broad” deﬁnition reﬂects a single HIV RNA level
of ≥200 copies/mL, the “restricted” deﬁnition includes a single
HIV RNA level of ≥400 copies/mL, and the “stringent” deﬁni-
tion uses a single HIV RNA level of ≥1000 copies/mL.
Statistical Methods
Baseline data are presented as number (%) or median (inter-
quartile range [IQR]). Characteristics of patients who developed
VF (deﬁned as HIV RNA levels ≥200, ≥400, and ≥1000 copies/
mL) and individuals who did not experience VF in each case
were compared using χ² tests or Fisher’s exact tests where ap-
propriate for categorical data and non-parametric Wilcoxon
rank-sum tests for continuous data. To assess the predictive
value of LLV as well as the inﬂuence of various demographic
and clinical parameters on the occurrence of VF, univariable
and multivariable Cox proportional hazards regression models
were applied. For each deﬁnition of VF (HIV RNA levels of
≥200, ≥400, and ≥1000 copies/mL) models were run sepa-
rately. Multivariable models were adjusted for age and VL at
baseline, CD4 count at baseline, HIV transmission category, na-
tionality, and prior cART interruptions. Adjusted time-to-event
curves were performed, holding all adjusted covariables ﬁxed at
their mean level. The proportional hazards assumptions were
assessed by testing for zero slopes of the scaled Schoenfeld
residuals.
Additional sensitivity analyses were run for different criteria
in patient selection: one analysis was performed without consid-
ering a VL measurement below the limit of detection (BLD) or
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BLQ in treatment history in order to exclude patients with very
short cART durations; one analysis was performed excluding
patients with cART interruptions or a cART stop after baseline
VL measurement; one analysis was conducted regarding a
shorter recruitment period of 6 months instead of 12 months;
one analysis included patients receiving unmodiﬁed cART for
Figure 1. Flowchart of inclusion criteria in patient selection. Abbreviations: BLD, below the limit of detection; BLQ, below the limit of quantification; cART, combination
antiretroviral therapy; INSTI, integrase inhibitor; LLV, low-level viremia; NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor;
PI/r, boosted protease inhibitor; VF, virological failure; VL, viral load.
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>9 months instead of >6 months; and ﬁnally, one analysis was
performed with a shorter recruitment period of 6 months, an
unmodiﬁed cART for >3 months, and without cART interrup-
tions or a cART stop after baseline VL measurement. All analyses
were conducted using Stata software, version 13.1 (StataCorp,
College Station, TX).
RESULTS
Patient Characteristics Stratiﬁed by Virological Failure
A total of 1775 patients fulﬁlled the inclusion criteria: 79 of
them with a VF of ≥200 copies/mL and another 82 of them
without any further VL measurement after baseline were ex-
cluded. Therefore, 1614 patients were eligible for analyses (Fig-
ure 1) in this study. Differences in demographic and laboratory
characteristics between the patients who developed VF and in-
dividuals who did not experience VF are described in Table 1.
Stratiﬁcation was made according to the 3 deﬁnitions of VF;
therefore, 68 (4.2%), 44 (2.7%), and 34 (2.1%) of 1614 incorpo-
rated patients progressed to a VF deﬁned as an HIV RNA level
of ≥200, ≥400, and ≥1000 copies/mL, respectively. Median fol-
low-up time for all patients regarding VF of ≥200 copies/mL as
endpoint was 9.2 months (IQR, 7.8–11.5). Each VF group dif-
fered signiﬁcantly from the non-VF group in VL at baseline, age
at baseline, HIV transmission category, CD4 count at baseline,
prior cART interruptions, as well as cART regimen. Compared
with individuals who experienced VF, patients who did not de-
velop a VF were older and had a higher CD4 cell count at base-
line. The proportion of injecting drug users (IDUs) was higher,
and there were fewer men who have sex with men (MSM) in the
VF group. Patients who had a VF≥ 400 and ≥1000 copies/mL
originated more frequently from high-prevalence countries. Pa-
tients with VF had more prior cART interruptions, were more
often on 2 NRTIs with a PI/r instead of a NNRTI or an INSTI,
and VL at baseline was higher compared with individuals who
did not experience VF. More importantly, in patients who had a
VF deﬁned as HIV RNA levels of ≥200 copies/mL, VL before
initiating cART was higher compared with the non-VF group,
but not for patients with VF deﬁned as HIV RNA level of ≥400
and ≥1000 copies/mL. No difference between the groups could
be found in ever having had a VF before VL at baseline, in prior
cART duration and in ﬁrst-line cART of the respective regimen.
Predictors of Virological Failure
Table 2 provides results from univariable and multivariable Cox
proportional hazards models for the occurrence of VF accord-
ing to the broad deﬁnition of VF (deﬁned as HIV RNA level of
≥200 copies/mL). Hazard ratios (HRs) for the development of
VF regarding the restricted and stringent deﬁnition of VF (de-
ﬁned as HIV RNA level of ≥400 and ≥1000 copies/mL, respec-
tively) are shown in the Supplemental Table 1. A total of 1614
patients were observed until the development of VF or last VL
measurement or death, whichever came ﬁrst.
In univariable models, several signiﬁcant factors turned out
to be associated with the development of VF. These factors
were (1) a higher VL at baseline (compared with patients who
were BLD or BLQ), (2) a lower CD4 cell count at baseline (com-
pared with patients with ≥500 cells/μL), (3) younger age (<30
years compared with above 50 years), (4) IDU, (5) women
who acquired HIV through heterosexual contact (compared
with MSM), (6) patient origin from high-prevalence countries
(compared with low-prevalence countries), (7) prior cART in-
terruptions (compared with uninterrupted cART), (8) 2 NRTI
with a PI/r as cART regimen (compared with 2 NRTI with an
NNRTI or INSTI), and ﬁnally (9) a higher VL before initiating
cART (compared with a VL ≤9.999 copies/mL).
Multivariable Cox proportional hazards models for each def-
inition of VF were calculated and controlled for VL at baseline,
CD4 count at baseline, age at baseline, HIV transmission cate-
gory, nationality, and prior cART interruptions. The resulting
adjusted cumulative hazard curves are shown in Figure 2. Com-
pared with patients who were BLD or BLQ, patients with a
quantiﬁable VL of ≤50 copies/mL at baseline had a 2.19 times
higher risk of VF of ≥200 copies/mL; however, this did not en-
compass the restricted and stringent deﬁnition of VF. Viral load
between 51 and 199 copies/mL at baseline also increased the
risk of VF ≥200 copies/mL, compared with patients who were
BLD or BLQ at baseline (HR = 4.21, 95% CI = 2.15–8.22). In ad-
dition, a trend for a higher risk of VF ≥400 and ≥1000 copies/
mL could be found (HR = 2.13, 95% CI = 0.84–5.39 and
HR = 2.52, 95% CI = 0.96–6.60, respectively). The association
between lower CD4 count at baseline and the development of
VF found in univariable analyses vanished after adjustment.
The hazard ratio for VF was higher in patients under 30 years
compared with individuals older than 50 years: HIV RNA
levels of ≥200 copies/mL, HR = 2.98 and 95% CI = 1.24–7.21;
HIV RNA levels of ≥400 copies/mL, HR = 3.67 and 95%
CI = 1.13–11.96; HIV RNA levels of ≥1000 copies/mL,
HR = 5.02 and 95% CI = .20–21.04, respectively. Injecting
drug use was associated with an increased risk of VF in
males: HIV RNA levels of ≥200 copies/mL, HR = 3.21 and
95% CI = 1.50–6.88; HIV RNA levels of ≥400 copies/mL,
HR = 4.57 and 95% CI = 1.85–11.33; HIV RNA levels of
≥1000 copies/mL, HR = 5.25 and 95% CI = 1.81–15.22, respec-
tively, compared with MSM. Injecting drug use was also associ-
ated with an increased risk of VF in females: HIV RNA levels of
≥200 copies/mL, HR = 3.83 and 95% CI = 1.25–11.74; HIV
RNA levels of ≥400 copies/mL, HR = 4.52 and 95% CI = 1.20–
17.03, respectively, compared with MSM. Female heterosexuals
showed a higher risk of VF of ≥200 copies/mL (HR = 2.25,
95% CI = 1.08–4.66), but not for VF deﬁned by higher VL levels.
Patients originating from high-prevalence countries were at
higher risk to develop VF ≥1000 copies/mL compared with
individuals from low-prevalence countries (HR = 2.94, 95%
CI = 1.03–8.43). The hazard ratio of VF for all 3 deﬁnitions was
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Table 1. Characteristics of Patients Stratified by Virological Failure Defined as HIV RNA Levels ≥200, ≥400, and ≥1000 copies/mL vs Nonvirological
Failure in Each Casea
All Patients (N = 1614) All Patients (N = 1614) All Patients (N = 1614)
Broad Definition Restricted Definition Stringent Definition
VL < 200 VF≥ 200 VL < 400 VF≥ 400 VL < 1000 VF≥ 1000
N= 1546 N = 68 N = 1570 N = 44 N = 1580 N = 34
No. of Patients N (%) N (%) P Value N (%) N (%) P Value N (%) N (%) P Value
VL at baseline <.001 .012 .008
51–199 copies/mL 62 (4.0) 13 (19.1) 69 (4.4) 6 (13.6) 69 (4.4) 6 (17.7)
≤50 copies/mL 103 (6.7) 9 (13.2) 108 (6.9) 4 (9.1) 110 (7.0) 2 (5.9)
BLD + BLQ 1381 (89.3) 46 (67.7) 1393 (88.7) 34 (77.3) 1401 (88.7) 26 (76.5)
Age at baseline .028 .045 .019
<30 yr 141 (9.1) 11 (16.2) 145 (9.3) 7 (15.9) 146 (9.3) 6 (17.7)
30–50 yr 996 (64.4) 47 (69.1) 1011 (64.4) 32 (72.7) 1018 (64.4) 25 (73.5)
>50 yr 409 (26.5) 10 (14.7) 414 (26.4) 5 (11.4) 416 (26.3) 3 (8.8)
HIV transmission category <.001 <.001 .001
Male injecting drug user 133 (8.6) 14 (20.6) 135 (8.6) 12 (27.3) 137 (8.7) 10 (29.4)
Female injecting drug user 46 (3.0) 4 (5.9) 47 (3.0) 3 (6.8) 48 (3.0) 2 (5.9)
Male heterosexual 340 (22.0) 8 (11.8) 343 (21.9) 5 (11.4) 343 (21.7) 5 (14.7)
Female heterosexual 339 (21.9) 21 (30.9) 348 (22.2) 12 (27.3) 351 (22.2) 9 (26.5)
Other 65 (4.2) 6 (8.8) 68 (4.3) 3 (6.8) 69 (4.4) 2 (5.9)
Men who have sex with men 623 (40.3) 15 (22.1) 629 (40.1) 9 (20.5) 632 (40.0) 6 (17.7)
Nationality .133 .012 .005
High prevalence country 143 (9.3) 10 (14.7) 144 (9.2) 9 (20.5) 145 (9.2) 8 (23.5)
Low prevalence country 1403 (90.8) 58 (85.3) 1426 (90.8) 35 (79.6) 1435 (90.8) 26 (76.5)
CD4 count at baseline .001 .015 .015
Missing 41 (2.7) 7 (10.3) 44 (2.8) 4 (9.1) 45 (2.9) 3 (8.8)
<200 cells/µL 48 (3.1) 5 (7.4) 49 (3.1) 4 (9.1) 49 (3.1) 4 (11.8)
200–349 cells/µL 174 (11.3) 7 (10.3) 176 (11.2) 5 (11.4) 176 (11.1) 5 (14.7)
350–499 cells/µL 264 (17.1) 12 (17.7) 267 (17.0) 9 (20.5) 271 (17.2) 5 (14.7)
≥500 cells/µL 1019 (65.9) 37 (54.4) 1034 (65.9) 22 (50.0) 1039 (65.8) 17 (50.0)
Prior cART interruptionsb <.001 <.001 <.001
≥1 339 (21.9) 30 (44.1) 348 (22.2) 21 (47.7) 352 (22.3) 17 (50.0)
None 1207 (78.1) 38 (55.9) 1222 (77.8) 23 (52.3) 1228 (77.7) 17 (50.0)
cART regimen .001 .024 .026
2 NRTI + PI/r 611 (39.5) 40 (58.8) 626 (39.9) 25 (56.8) 631 (39.9) 20 (58.8)
2 NRTI + NNRTI/INSTI 935 (60.5) 28 (41.2) 944 (60.1) 19 (43.2) 949 (60.1) 14 (41.2)
Ever VF before VL at baseline .140 .340 .373
<200 copies/mL 83 (5.4) 2 (2.9) 83 (5.3) 2 (4.6) 84 (5.3) 1 (2.9)
200–399 copies/mL 416 (26.9) 26 (38.2) 428 (27.3) 14 (31.8) 430 (27.2) 12 (35.3)
400–999 copies/mL 303 (19.6) 8 (11.8) 307 (19.6) 4 (9.1) 308 (19.5) 3 (8.8)
≥1000 copies/mL 744 (48.1) 32 (47.1) 752 (47.9) 24 (54.6) 758 (48.0) 18 (52.9)
VL before initiating cART .045 .399 .330
Missing 272 (17.6) 13 (19.1) 277 (17.6) 8 (18.2) 280 (17.7) 5 (14.7)
>99.999 copies/mL 559 (36.2) 34 (50.0) 573 (36.5) 20 (45.5) 577 (36.5) 16 (47.1)
10.000–99.999 copies/mL 527 (34.1) 18 (26.5) 531 (33.8) 14 (31.8) 533 (33.7) 12 (35.3)
≤9.999 copies/mL 188 (12.2) 3 (4.4) 189 (12.0) 2 (4.6) 190 (12.0) 1 (2.9)
Prior cART durationc 1.000 .873 .710
<9 mo 61 (4.0) 2 (2.9) 61 (3.9) 2 (4.6) 61 (3.9) 2 (5.9)
9–18 mo 139 (9.0) 6 (8.8) 141 (9.0) 4 (9.1) 142 (9.0) 3 (8.8)
>18 mo 1346 (87.1) 60 (88.2) 1368 (87.1) 38 (86.4) 1377 (87.2) 29 (85.3)
Antiretroviral therapy-naived .146 .218 .181
Yes 290 (18.8) 8 (11.8) 293 (18.7) 5 (11.4) 295 (18.7) 3 (8.8)
No 1256 (81.2) 60 (88.2) 1277 (81.3) 39 (88.6) 1285 (81.3) 31 (91.2)
Follow-up time in months 9.3 (8.0–11.5) 6.4 (3.3–8.2) <.001 9.4 (8.0–11.5) 7.0 (5.0–8.4) <.001 9.4 (8.0–11.6) 7.1 (5.8–8.7) <.001
Abbreviations: BLD, below the limit of detection; BLQ, below the limit of quantification; cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; INSTI, integrase inhibitor;
NNRTI, nonnucleoside reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI/r, boosted protease inhibitor; RNA, ribonucleic acid; VF, virological failure; VL, viral load.
a The first VL measurement after baseline VL measurement (baseline: the first detectable VL measurement within 6 months after receiving unmodified cART for >6 months with standard
regimens between July 2012 and 2013, excluding patients without any VLmeasurement BLQ in their treatment history as well as patients without any baseline VLmeasurement). [Number (%)
or median (interquartile range)].
b Interruptions prior to 6 months of unmodified cART of the respective cART regimen.
c cART duration until 6 months of unmodified cART of the respective cART regimen.
d Whether the respective cART regimen is a first-line cART or not.
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higher in patients who have had prior cART interruptions: HIV
RNA levels of ≥200 copies/mL, HR = 2.28 and 95% CI = 1.37–
3.77; HIV RNA levels ≥400 copies/mL, HR = 2.77 and 95%
CI = 1.48–5.19; HIV RNA levels ≥1000 copies/mL, HR = 2.88
and 95% CI = 1.41–5.87. However, all additional analyses did
Table 2. Univariable and Multivariable Cox Regression Results:
Association Between Different Factors and Virological Failure Defined
as HIV RNA Levels ≥200 Copies/mL (Broad Definition)
Outcome VF≥ 200
No. of Patients Included N = 1614
No. of Failures N = 68
Univariable Multivariable
HR (95% CI) HR (95% CI)
VL at baseline
51–199 copies/mL 5.84 (3.15–10.82) 4.21 (2.15–8.22)
≤50 copies/mL 2.47 (1.21–5.05) 2.19 (1.06–4.55)
BLD + BLQ 1.00 (Reference) 1.00 (Reference)
Age at baseline
<30 y 3.31 (1.41–7.81) 2.98 (1.24–7.21)
30–50 yr 1.94 (.98–3.84) 1.91 (.95–3.84)
>50 yr 1.00 (Reference) 1.00 (Reference)
HIV transmission category
Male injecting drug user 4.53 (2.19–9.40) 3.21 (1.50–6.88)
Female injecting drug user 3.83 (1.27–11.54) 3.83 (1.25–11.74)
Male heterosexual 1.00 (.42–2.35) 1.07 (.44–2.59)
Female heterosexual 2.64 (1.36–5.13) 2.25 (1.08–4.66)
Other 3.72 (1.44–9.59) 3.66 (1.40–9.56)
Men who have sex with men 1.00 (Reference) 1.00 (Reference)
Nationality
High prevalence country 1.62 (.83–3.16) 1.07 (.48–2.36)
Low prevalence country 1.00 (Reference) 1.00 (Reference)
CD4 count at baseline
Missing 4.60 (2.05–10.32) 3.31 (1.40–7.81)
<200 cells/µL 2.91 (1.14–7.41) 1.66 (.62–4.43)
200–349 cells/µL 1.11 (.50–2.49) 0.95 (.42–2.16)
350–499 cells/µL 1.25 (.65–2.39) 1.48 (.76–2.87)
≥500 cells/µL 1.00 (Reference) 1.00 (Reference)
Prior cART interruptionsa
≥1 2.80 (1.73–4.52) 2.28 (1.37–3.77)
None 1.00 (Reference) 1.00 (Reference)
cART regimen
2 NRTI + PI/r 2.13 (1.31–3.45)
2 NRTI + NNRTI/INSTI 1.00 (Reference)
Ever VF before VL at baseline
<200 copies/mL 0.58 (.14–2.42)
200–399 copies/mL 1.40 (.84–2.36)
400–999 copies/mL 0.59 (.27–1.29)
≥1000 copies/mL 1.00 (Reference)
VL before initiating cART
Missing 2.91 (.83–10.21)
>99.999 copies/mL 3.49 (1.07–11.37)
10.000–99.999 copies/mL 2.10 (.62–7.14)
≤9.999 copies/mL 1.00 (Reference)
Prior cART durationb
<9 mo 0.85 (.21–3.47)
9–18 mo 0.96 (.42–2.22)
>18 mo 1.00 (Reference)
Antiretroviral therapy-naivec
Yes 0.55 (.26–1.15)
No 1.00 (Reference)
Abbreviations: BLD, below the limit of detection; BLQ, below the limit of quantification; cART,
combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency
virus; HR, hazard ratio; INSTI, integrase inhibitor; NNRTI, nonnucleoside reverse-
transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhibitor; PI/r, boosted
protease inhibitor; RNA, ribonucleic acid; VF, virological failure; VL, viral load.
a Interruptions prior to 6 months of unmodified cART of the respective cART regimen.
b cART duration until 6 months of unmodified cART of the respective cART regimen.
c Whether the respective cART regimen is a first-line cART or not.
Figure 2. Adjusted cumulative hazard curves for the development of virological
failure based on a single viral load at baseline. Abbreviations: BLD, below the
limit of detection; BLQ, below the limit of quantification; CI, confidence interval;
HR, hazards ratio; LLV, low-level viremia.
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not reveal any substantial differences in HRs compared with our
primary analysis (data not shown).
DISCUSSION
In this study, we speciﬁcally investigated the impact of LLV on
VF, deﬁned as HIV RNA level of ≥200, ≥400, and ≥1000 cop-
ies/mL, among a cohort of HIV-positive individuals in Austria
on unmodiﬁed cART with standard regimens over a recent pe-
riod of more than 6 months. Other potential risk factors were
also studied.
We observed that 1 single measurement of quantiﬁable VL
below 200 copies/mL under unmodiﬁed cART predicted the oc-
currence of VF, according to the broad deﬁnition of VF (≥200
copies/mL). The risk to develop such VF was 2.19 times higher
for individuals whose VL was ≤50 copies/mL and 4.21 times
higher for those with VL of 51–199 copies/mL compared with
patients who were BLD or BLQ at baseline. This ﬁnding was in-
dependent of other covariates including CD4 count at baseline,
age at baseline, HIV transmission category, nationality, and
prior cART interruptions, which may inﬂuence the outcome.
Regarding the restricted and the stringent deﬁnition of VF, a
trend for an increased risk of VF could be found in patients hav-
ing had a VL of 51–199 copies/mL at baseline.
Our results extend and reﬁne data from several recent studies
showing the predictive value of LLV. Although these studies dif-
fer in study designs and methods, they all conclude that persis-
tent LLV (determined by repeated measurements) elevates the
risk of VF [6–11].
In clinical routine healthcare, providers encounter 1 single
measurement of VL. Only 1 study has hitherto addressed this
important issue; however, a different commercial HIV RNA
assay was used in this study, namely the Abbott RealTime
assay. It pointed out the strong predictive value for VF in pa-
tients with 1 single VL measurement below 50 copies/mL
[13]. Our study, based on the Roche Cobas AmpliPrep/Cobas
TaqMan 2.0 assay, essentially conﬁrms these data, but we pro-
vide more detail and use this in conjunction with other param-
eters. In our study, the risk of the development of VF decreased
with increasing age and escalated with stricter threshold deﬁni-
tions of VF. However, our ﬁnding that younger age was an in-
dependent factor of viral rebound in patients with a single
measurement of VL <50 copies/mL was also conﬁrmed by
other studies [17, 18]; however, these were studies on persistent
LLV. In addition, we demonstrated a higher risk of VF in male
and female IDUs compared with MSM. The risk was higher in
men and increased with higher VF thresholds. In our study, pa-
tients from high-prevalence countries had an almost 3-fold higher
risk of experiencing VF ≥1000 copies/mL after a single measure-
ment of LLV, similar to the correlation to persistent LLV [17].
Because adherence to therapy is difﬁcult to measure accurate-
ly, cART interruptions before 6 months under stable cART of
the respective cART regimen were considered as a proxy for
adherence. Treatment interruptions, deﬁned as cART discon-
tinuation for at least 8 days after having started cART, were ob-
served more frequently in patients who developed VF
(approximately 44% vs 22%). In adjusted analyses, the risk of
VF of ≥200 was 2.3-fold higher in patients who had prior
cART interruptions compared with those who never interrupt-
ed treatment. As a consequence, we demonstrated reduced ad-
herence as a predictor of VF. Doyle et al [13] found major
resistance-associated mutations in less than half of the patients
with rebound of >400 copies/mL, and they concluded that
poor adherence was as a cause of rebound. A decline in VF
was shown for patients who have had virologic suppression for
longer time periods than individuals suppressed for shorter peri-
ods [19, 20].However, in our study, prior cART duration did not
predict VF. We recently found that duration of cART is signiﬁ-
cantly associated with LLV [21], which is in line with other re-
ports [22, 23] but not all [24].
Furthermore, we found that the type of cART regimen was
associated with low-level rebound [8] and that NNRTI-based
regimens were able to exert a stronger inhibitory effect on
viral replication than PI-based regimens [13, 25, 26]. In a previ-
ous study, we showed that patients BLD or BLQ were more like-
ly to be treated with 2 NRTIs and an NNRTI or INSTI
compared with those with LLV, most of whom tended to be
on 2 NRTIs and a PI/r. In contrast, we found a 1.5-fold
increased risk of LLV for patients receiving cART with a PI/
r-based regimen compared with those on a NNRTI- or INSTI-
based regimen [21]. However, this effect could be confounded
by a selection bias because PI/r-based cART regimens may pref-
erentially be prescribed to individuals with concerns regarding
adherence. A recent retrospective study in patients on cART
with viremia between 50 and 100 copies/mL found that plasma
drug levels at the ﬁrst LLV episode were associated with subse-
quent VF, which was deﬁned as HIV RNA ≥1000 copies/mL. In
addition, it was shown that together with resistance data, a high-
er proportion of treatment failures can be explained than either
measure alone [27]. However, at this time, HIV cannot be erad-
icated by cART; therefore, despite being on stable cART, it re-
mains a challenge for some patients to achieve HIV RNA levels
BLD or BLQ [28]. Low-level viremia might arise from the fol-
lowing: (1) ongoing cycles of viral replication in a sanctuary site
where drug levels are suboptimal; (2) long-lived infected cells
that produce virus; or (3) activation of virus expression from la-
tently infected CD4 T-cell reservoirs [29]. Studies on the effect of
cART intensiﬁcation in patients with LLV did not ﬁnd evidence
of ongoing replication [30], whereas others concluded that active
replication persists in some individuals on cART [31]. In our
study, only a small proportion of the patients with VL BLD or
BLQ at baseline experienced a VF of ≥200 copies/mL (3%).
A major strength of this study is the open, observational design
with complete follow up. Our study provides data of HIV-positive
individuals in Austria and is representative of an entire country;
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therefore, selection bias was minimized. This study has several lim-
itations. There was a small number of VFs, especially with regard
to the stringent deﬁnition, which limits the number of variables for
which the analysis could be adjusted. We were not able to adjust
for several parameters that might inﬂuence cART pharmacokinet-
ics such as body mass index and renal function. However, no as-
sociation could be found between these factors and LLV [7].
Furthermore, we were not able to adjust for socioeconomic and
lifestyle factors such as smoking, which may also inﬂuence the re-
sults, because of missing or incomplete data. Moreover, we did not
analyze the association between VF and the development of resis-
tance mutations. Previous studies documented the risk of acquir-
ing resistance mutations during LLV [32, 33] and in patients who
experienced rebound [13].
CONCLUSIONS
This study of well deﬁned patients on unmodiﬁed cART over a
period of more than 6 months gives insights into different pre-
dictors for the development of VF. Our main ﬁnding of an in-
creased risk of VF in patients with 1 single quantiﬁable VL
measurement below 200 copies/mL supports the need to evaluate
strategies for managing LLV in cART-treated patients. These re-
sults provide implications for patient management by emphasiz-
ing closer monitoring and adherence counseling. Furthermore,
our ﬁndings could form the basis for future methods and strat-
egies to improve the outcome in single quantiﬁable VL studies.
Supplementary Data
Supplementary material is available online atOpen Forum Infectious Diseases
online (http://OpenForumInfectiousDiseases.oxfordjournals.org/).
Acknowledgments
We are grateful to all clinicians, data managers, and research nurses in
participating human immunodeﬁciency virus (HIV) treatments centers listed
in the Appendix. Furthermore, a special thank goes to DI Heinz Appoyer
(now called network vita) who developed the HIV Patient Management
System.
Disclaimer. Companies involved in marketing HIV drugs (AbbVie,
Boehringer-Ingelheim, Bristol-Myers-Squibb, GILEAD, GSK Austria on
behalf of Viif, Janssen, MSD) provided equal contributions, irrespective of
their market shares.
Financial support. This work was funded by the Austrian Agency for
Health and Food Safety (AGES), participating hospitals running HIV treat-
ment centers, and partners in the pharmaceutical industry.
Potential conﬂicts of interest. All authors: No reported conﬂicts. All
authors have submitted the ICMJE Form for Disclosure of Potential Con-
ﬂicts of Interest.
References
1. European Guidelines for treatment of HIV-infected adults in Europe, Version 8.0,
October 2015. European AIDS Clinical Society. Brussels, Belgium, 2015. Available
at: http://www.eacsociety.org/ﬁles/2015_eacsguidelines_8.0-english_revised-
20151104.pdf. Accessed 25 March 2016.
2. British HIV Association guidelines for the treatment of HIV-1-positive adults
with antiretroviral therapy 2015. British HIV Association, 2015. Available at:
http://www.bhiva.org/documents/Guidelines/Treatment/2015/2015-treatment-
guidelines.pdf. Accessed 25 March 2016.
3. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the
use of antiretroviral agents in HIV-1-infected adults and adolescents. Department
of Health and Human Services. Rockville, MD, 2016. Available at: https://aidsinfo.
nih.gov/contentﬁles/lvguidelines/adultandadolescentgl.pdf. Accessed 25March 2016.
4. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV in-
fection: 2014 recommendations of the International Antiviral Society-USA Panel.
JAMA 2014; 312:410–25.
5. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating
and Preventing HIV Infection: What’s New. World Health Organization.
Geneva; 2015. Available at: http://apps.who.int/iris/bitstream/10665/198064/1/
9789241509893_eng.pdf?ua=1. Accessed 25 March 2016.
6. Antiretroviral Therapy Cohort Collaboration (ART-CC), Vandenhende MA, Ingle
S, et al. Impact of low-level viremia on clinical and virological outcomes in treated
HIV-1-infected patients. AIDS 2015; 29:373–83.
7. Boillat-Blanco N, Darling KE, Schoni-Affolter F, et al. Virological
outcome and management of persistent low-level viraemia in HIV-1-infected
patients: 11 years of the Swiss HIV Cohort Study. Antivir Ther 2015; 20:
165–75.
8. Geretti AM, Smith C, Haberl A, et al. Determinants of virological failure after suc-
cessful viral load suppression in ﬁrst-line highly active antiretroviral therapy. Anti-
vir Ther 2008; 13:927–36.
9. Laprise C, de Pokomandy A, Baril JG, et al. Virologic failure following persistent
low-level viremia in a cohort of HIV-positive patients: results from 12 years of ob-
servation. Clin Infect Dis 2013; 57:1489–96.
10. Pernas B, Grandal M, Pertega S, et al. Any impact of blips and low-level viraemia
episodes among HIV-infected patients with sustained virological suppression on
ART? J Antimicrob Chemother 2016; 71:1051–5.
11. Sungkanuparph S, Groger RK, Overton ET, et al. Persistent low-level viraemia and
virological failure in HIV-1-infected patients treated with highly active antiretro-
viral therapy. HIV Med 2006; 7:437–41.
12. Vandenhende MA, Perrier A, Bonnet F, et al. Risk of virological failure in HIV-1-
infected patients experiencing low-level viraemia under active antiretroviral ther-
apy (ANRS C03 cohort study). Antivir Ther 2015; 20:655–60.
13. Doyle T, Smith C, Vitiello P, et al. Plasma HIV-1 RNA detection below 50 copies/
ml and risk of virologic rebound in patients receiving highly active antiretroviral
therapy. Clin Infect Dis 2012; 54:724–32.
14. Sire JM, Vray M, Merzouk M, et al. Comparative RNA quantiﬁcation of HIV-1
group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1
v2.0 and Abbott Real-Time HIV-1 PCR assays. J Acquir Immune Deﬁc Syndr
2011; 56:239–43.
15. Taylor N, Grabmeier-Pﬁstershammer K, Egle A, et al. Cobas ampliprep/cobas Taq-
Man HIV-1 v2.0 assay: consequences at the cohort level. PLoS One 2013; 8:e74024.
16. Swenson LC, Cobb B, Geretti AM, et al. Comparative performances of HIV-1 RNA
load assays at low viral load levels: results of an international collaboration. J Clin
Microbiol 2014; 52:517–23.
17. Bansi LK, Benzie AA, Phillips AN, et al. Are previous treatment interruptions as-
sociated with higher viral rebound rates in patients with viral suppression? AIDS
2008; 22:349–56.
18. Henrich TJ, Wood BR, Kuritzkes DR. Increased risk of virologic rebound in pa-
tients on antiviral therapy with a detectable HIV load <48 copies/mL. PLoS One
2012; 7:e50065.
19. Lima VD, Bangsberg DR, Harrigan PR, et al. Risk of viral failure declines with du-
ration of suppression on highly active antiretroviral therapy irrespective of adher-
ence level. J Acquir Immune Deﬁc Syndr 2010; 55:460–5.
20. Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR. The risk of virologic
failure decreases with duration of HIV suppression, at greater than 50% adherence
to antiretroviral therapy. PLoS One 2009; 4:e7196.
21. Leierer G, Grabmeier-Pﬁstershammer K, Steuer A, et al. Factors associated with
low-level viraemia and virological failure: results from the Austrian HIV cohort
study. PLoS One 2015; 10:e0142923.
22. Pascual-Pareja JF, Martinez-Prats L, Luczkowiak J, et al. Detection of HIV-1 at be-
tween 20 and 49 copies per milliliter by the Cobas TaqMan HIV-1 v2.0 assay is
associated with higher pretherapy viral load and less time on antiretroviral therapy.
J Clin Microbiol 2010; 48:1911–2.
23. Vancoillie L, Demecheleer E, Callens S, et al. Markers associated with persisting
low-level viraemia under antiretroviral therapy in HIV-1 infection. J Antimicrob
Chemother 2014; 69:1098–103.
24. Charpentier C, Landman R, Laouenan C, et al. Persistent low-level HIV-1 RNA
between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors
and virological outcome. J Antimicrob Chemother 2012; 67:2231–5.
25. Bonora S, Nicastri E, Calcagno A, et al. Ultrasensitive assessment of residual HIV
viraemia in HAART-treated patients with persistently undetectable plasma HIV-
RNA: a cross-sectional evaluation. J Med Virol 2009; 81:400–5.
26. Widdrington J, Payne B, Medhi M, et al. The signiﬁcance of very low-level virae-
mia detected by sensitive viral load assays in HIV infected patients on HAART.
J Infect 2011; 62:87–92.
27. Gonzalez-Serna A. Untimed drug levels and resistance in patients experiencing
low-level viremia. In: Conference on Retroviruses and Opportunistic Infections.
Seattle, Washington. February 23–26, 2015. (Abstract 117).
8 • OFID • Leierer et al
 at Zentralbibliothek on A
ugust 4, 2016
http://ofid.oxfordjournals.org/
D
ow
nloaded from
 
28. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least
7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S
A 2008; 105:3879–84.
29. Palmer S, Josefsson L, Cofﬁn JM. HIV reservoirs and the possibility of a cure for
HIV infection. J Intern Med 2011; 270:550–60.
30. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensiﬁcation
does not reduce persistent low-level viremia in patients with HIV-1 suppression
during receipt of combination antiretroviral therapy. Clin Infect Dis 2010;
50:912–9.
31. Buzon MJ, Massanella M, Llibre JM, et al. HIV-1 replication and immune dynam-
ics are affected by raltegravir intensiﬁcation of HAART-suppressed subjects. Nat
Med 2010; 16:460–5.
32. Nettles RE, Kieffer TL, Simmons RP, et al. Genotypic resistance in HIV-1-infected
patients with persistently detectable low-level viremia while receiving highly active
antiretroviral therapy. Clin Infect Dis 2004; 39:1030–7.
33. Taiwo B, Gallien S, Aga E, et al. Antiretroviral drug resistance in HIV-1-infected
patients experiencing persistent low-level viremia during ﬁrst-line therapy. J Infect
Dis 2011; 204:515–20.
APPENDIX
The Austrian HIV Cohort Study ([AHIVCOS] Steering Com-
mittee): Alexander Egle, Maria Geit, Bernhard Haas, Manfred Ka-
natschnig, Armin Rieger, Andrea Steuer, Robert Zangerle (Chair).
HIV Treatment Centers: LKH Innsbruck (coordinating cen-
ter): Martin Gisinger, Maria Kitchen, Elisabeth Rieser, Brigitte
Rühr, Mario Sarcletti, Robert Zangerle. LKH Salzburg: Alexander
Egle, Richard Greil, Michaela Schachner, Ninon Taylor. AKH
Linz: Jörg Berg, Maria Geit, Angela Öllinger. AKH Vienna: Regi-
na Aichwalder, Katharina Grabmeier-Pﬁstershammer, Armin
Rieger, Veronique Touzeau. Otto-Wagner Hospital Vienna:
Piotr Cichon, Manfred Gartner, Brigitte Schmied, Andrea Steuer.
LKH Graz-West: Bernhard Haas, Andreas Kapper, Elmar Wall-
ner. LKH Klagenfurt: Silvana Achatz, Manfred Kanatschnig,
Georg Schober.
Virology: Elisabeth Puchhammer-Stöckl (Vienna).
Data Management Group: Heinz Appoyer (IT-related),
Gisela Leierer (AHIVCOS), Michaela Rappold (AHIVCOS),
Stefanie Strickner (AHIVCOS).
Data Safety and Protection: Klaus Schindelwig (Innsbruck).
Scientiﬁc Advisory Board: Bruno Ledergerber (Zurich),
Gerd Fätkenheuer (Cologne).
Viral Load Predicts Virological Failure • OFID • 9
 at Zentralbibliothek on A
ugust 4, 2016
http://ofid.oxfordjournals.org/
D
ow
nloaded from
 
